New chemo cocktail aims to shrink pancreatic tumors
NCT ID NCT07076212
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and cisplatin every four weeks. The goal is to see which combination shrinks more tumors. The trial is recruiting 52 adults who have not had prior treatment for their cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy combination (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin vs gemcitabine, nab-paclitaxel, cisplatin)
What this could lead to
If NALIRIFOX works better than the other combo, it could become a new standard treatment for advanced pancreatic cancer, potentially shrinking more tumors and extending life.
What could go wrong
This is a small, early Phase 2 trial with only 52 people, so results may not apply to everyone. Chemotherapy has serious side effects, and the new combo might not be more effective than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hollings Cancer Center at Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of South Carolina Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••